fig2
Figure 2. Schema outlining biomarker-driven strategies to improve upon current evidence for immunotherapy in ovarian cancer. Current trials are focused on improving clinical outcomes by either overcoming resistance through synergistic therapeutics (rational immune sensitisation) or bypassing resistance mechanisms (choosing different therapeutic targets). FRα: folate receptor-alpha; IDO1: Indoleamine 2, 3-dioxygenase 1; PARP: Poly-ADP ribose polymerase.
